West Pharmaceutical Services (WST) stock
NYSE
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 2
- Market cap
- $27.5B
- As of Nov 5, 2026
- P/E
- 43.00x
- Trailing twelve months
- P/B
- 9.26x
- Latest reported equity
- P/S
- 8.09x
- Trailing twelve months
- ROE
- 21.5%
- Trailing twelve months
- Dividend yield
- 0.22%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $27.5B
- As of Nov 5, 2026
- P/E
- 43.00x
- Trailing twelve months
- P/B
- 9.26x
- Latest reported equity
- P/S
- 8.09x
- Trailing twelve months
- ROE
- 21.5%
- Trailing twelve months
- Dividend yield
- 0.22%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
43.00x
P/B
9.26x
P/S
8.09x
Earnings and dividend metrics▾
Earnings
EPS
$9.13
Earnings per share
BPS
$42.40
Book value per share
ROE
21.5%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $9.13 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $42.40 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 21.5%.
Dividends
Yield
0.22%
Dividend per share
$0.86
Payout ratio
9.5%
Consecutive years
18+ yrs
Yield uses fiscal 2025 dividends · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $86.00 before tax.
- Payout ratio — 9.5% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 18 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 8.7% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $805M+8.7%
$747M
Jul–Sep '24
$805M
Jul–Sep '25
$875M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 29, 2026.
- Earnings per share increased 57.3% from the same quarter a year earlier.
- Revenue increased 8.7% from the same quarter a year earlier.
- Operating income increased 58.9% from the same quarter a year earlier.
- Net income increased 52.9% from the same quarter a year earlier.
Filed Oct 29, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Favorite Annette FSr. VP & Chief HR Officer · Sep 15, 2026Open-market sale2,524 shares · $921KAvg. price $36521,818 shares held after
- Favorite Annette FSr. VP & Chief HR Officer · Sep 15, 2026Option exercise2,524 shares · $226KAvg. price $89.6424,342 shares held after
- Favorite Annette FSr. VP & Chief HR Officer · Sep 14, 2026Open-market sale2,500 shares · $888KAvg. price $35521,818 shares held after
- Favorite Annette FSr. VP & Chief HR Officer · Sep 14, 2026Option exercise2,500 shares · $224KAvg. price $89.6424,318 shares held after
- Favorite Annette FSr. VP & Chief HR Officer · Sep 11, 2026Open-market sale2,500 shares · $863KAvg. price $34521,818 shares held after
- Favorite Annette FSr. VP & Chief HR Officer · Sep 11, 2026Option exercise2,500 shares · $224KAvg. price $89.6424,318 shares held after
- Favorite Annette FSr. VP & Chief HR Officer · Sep 8, 2026Open-market sale8,135 shares · $2.8MAvg. price $340.8116,845 shares held after
Show 3 price lots
- 2,818 shares × $340.81$960K
- 2,817 shares × $340.81$960K
- 2,500 shares × $340.81$852K
- Favorite Annette FSr. VP & Chief HR Officer · Sep 8, 2026Option exercise8,135 shares · $694KAvg. price $85.3661
Show 3 price lots
- 2,818 shares × $83.47$235K
- 2,817 shares × $83.47$235K
- 2,500 shares × $89.64$224K
- McMahon Robert W.SVP & Chief Financial Officer · Aug 11, 2026Shares withheld for taxes3,109 shares · $1.1MAvg. price $351.37
Show 2 price lots
- 2,764 shares × $351.37$971K
- 346 shares × $351.37$121K
- McMahon Robert W.SVP & Chief Financial Officer · Aug 11, 2026Option exercise7,149 shares
Show 2 price lots
- 794 sharesValue not reported
- 6,355 sharesValue not reported
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QWest Pharmaceutical said consolidated net sales for the 3 months ended September 30, 2026 rose $69.9 million, or 8.7%. Excluding an unfavorable foreign currency translation impact of $4.0 million and the $18.0 million reduction in SmartDose 3.5mL product revenue, organic growth was $91.9 million, or 11.9%.Published Oct 29, 2026 · Filed Oct 29, 2026Read the summary →
- AI summary8-KWest Pharmaceutical said it entered into a New Credit Agreement with Bank of America, N.A. as administrative agent on October 26, 2026. The facility has a 5-year term, with revolving advances of up to $750 million and a term loan advance of $200 million on the Effective Date.Published Oct 26, 2026 · Filed Oct 26, 2026Read the summary →
- AI summary8-KThe company said it held its annual meeting of shareholders virtually on May 4, 2026. As of the record date, February 27, 2026, there were 72,081,610 shares of common stock outstanding, and 66,193,322 shares (91.83%) were represented at the meeting, it reported.Published Oct 2, 2026 · Filed May 5, 2026Read the summary →
- West Pharmaceutical said consolidated net sales for the 3 months ended September 30, 2026 rose $69.9 million, or 8.7%. Excluding an unfavorable foreign currency translation impact of $4.0 million and the $18.0 million reduction in SmartDose 3.5mL product revenue, organic growth was $91.9 million, or 11.9%.Read the full analysis →
- West Pharmaceutical said it entered into a New Credit Agreement with Bank of America, N.A. as administrative agent on October 26, 2026. The facility has a 5-year term, with revolving advances of up to $750 million and a term loan advance of $200 million on the Effective Date.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
West Pharmaceutical Services (WST) stock information
NYSE
West Pharmaceutical Services (WST) is listed on NYSE. Its market capitalization is about $27.5B. On trailing-twelve-month earnings the P/E ratio is 43, and the P/B ratio is 9.26. Return on equity is 21.5%. These figures are computed in-house from official filings and are reference information only.
West Pharmaceutical Services — frequently asked questions
- What is the P/E ratio of West Pharmaceutical Services (WST)?
- On a trailing-twelve-month basis, WST trades at a P/E ratio of 43. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of West Pharmaceutical Services?
- WST has a market capitalization of about $27.5B. The figure moves with the share price and is refreshed each trading day.
- Does West Pharmaceutical Services pay a dividend?
- WST has a dividend yield of about 0.22%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.